CD274 and type 2 diabetes mellitus: Nevertheless, a diabetic risk constellation and T2DM history could serve as a criterion for stratifying PDAC patients to apply PD-1/PD-L1 checkpoint inhibitors such as Pembrolizumab or Atezolizumab for immune therapy that otherwise may fail due to the absence of PD-L1 expression in many PDAC cases (see above) [32,38,55,56].